Torsten Dahlén

452 total citations
21 papers, 249 citations indexed

About

Torsten Dahlén is a scholar working on Hematology, Genetics and Oncology. According to data from OpenAlex, Torsten Dahlén has authored 21 papers receiving a total of 249 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Hematology, 7 papers in Genetics and 5 papers in Oncology. Recurrent topics in Torsten Dahlén's work include Chronic Myeloid Leukemia Treatments (9 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Eosinophilic Disorders and Syndromes (4 papers). Torsten Dahlén is often cited by papers focused on Chronic Myeloid Leukemia Treatments (9 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Eosinophilic Disorders and Syndromes (4 papers). Torsten Dahlén collaborates with scholars based in Sweden, United States and Denmark. Torsten Dahlén's co-authors include Gustaf Edgren, Jingcheng Zhao, Leif Stenke, Anders Själander, Martin Höglund, Magnus Björkholm, Johan Richter, Fredrik Sandin, Ulla Olsson‐Strömberg and Hanxin Zhang and has published in prestigious journals such as JAMA, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Torsten Dahlén

21 papers receiving 247 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Torsten Dahlén Sweden 10 126 66 45 44 40 21 249
Mutlu Karkucak Türkiye 12 40 0.3× 34 0.5× 37 0.8× 17 0.4× 39 1.0× 43 334
Valentina Pierini Italy 11 158 1.3× 63 1.0× 43 1.0× 26 0.6× 28 0.7× 31 484
Radu Vasilescu Belgium 8 128 1.0× 53 0.8× 20 0.4× 11 0.3× 263 6.6× 13 351
Sarah N. Gibbs United States 9 41 0.3× 32 0.5× 24 0.5× 21 0.5× 6 0.1× 25 228
Frode Krøll Norway 9 123 1.0× 24 0.4× 64 1.4× 12 0.3× 258 6.5× 15 384
R. E. Davis Australia 10 65 0.5× 37 0.6× 58 1.3× 21 0.5× 51 1.3× 19 336
Laura Pina Vegas France 10 61 0.5× 16 0.2× 24 0.5× 25 0.6× 185 4.6× 19 343
Jessica Samuelsson Sweden 8 96 0.8× 134 2.0× 15 0.3× 9 0.2× 81 2.0× 25 303
Corrado Masciullo Italy 6 162 1.3× 124 1.9× 6 0.1× 14 0.3× 41 1.0× 9 299
Peter Haas Germany 7 194 1.5× 58 0.9× 86 1.9× 6 0.1× 4 0.1× 23 368

Countries citing papers authored by Torsten Dahlén

Since Specialization
Citations

This map shows the geographic impact of Torsten Dahlén's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Torsten Dahlén with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Torsten Dahlén more than expected).

Fields of papers citing papers by Torsten Dahlén

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Torsten Dahlén. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Torsten Dahlén. The network helps show where Torsten Dahlén may publish in the future.

Co-authorship network of co-authors of Torsten Dahlén

This figure shows the co-authorship network connecting the top 25 collaborators of Torsten Dahlén. A scholar is included among the top collaborators of Torsten Dahlén based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Torsten Dahlén. Torsten Dahlén is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Clements, Mark, Nareg H. Roubinian, Jingcheng Zhao, et al.. (2025). An agnostic study of donor and component factors associated with transfusion‐related changes in laboratory markers. Transfusion. 65(5). 886–896. 2 indexed citations
2.
Dahlén, Torsten, et al.. (2024). Loss in Overall and Quality‐Adjusted Life Expectancy for Patients With Chronic‐Phase Chronic Myeloid Leukemia. European Journal Of Haematology. 114(2). 334–342. 3 indexed citations
3.
Dahlén, Torsten, et al.. (2024). Frequency of comedication of proton pump inhibitors with crystalline dasatinib in chronic myeloid leukemia and effects on TKI-bioavailability.. Journal of Clinical Oncology. 42(16_suppl). 6561–6561. 1 indexed citations
4.
Dahlén, Torsten, Jingcheng Zhao, Michael P. Busch, & Gustaf Edgren. (2024). Using routine health-care data to search for unknown transfusion-transmitted disease: a nationwide, agnostic retrospective cohort study. The Lancet Digital Health. 6(2). e105–e113. 2 indexed citations
5.
Zhao, Jingcheng, Klaus Rostgaard, Elsa Lauwers, et al.. (2023). Intracerebral Hemorrhage Among Blood Donors and Their Transfusion Recipients. JAMA. 330(10). 941–941. 16 indexed citations
6.
Dahlén, Torsten, Gustaf Edgren, Per Ljungman, et al.. (2022). Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Follow‐up of patients diagnosed 2002–2017 in a complete coverage and nationwide agnostic register study. American Journal of Hematology. 97(4). 421–430. 8 indexed citations
7.
Dahlén, Torsten, Mark Clements, Jingcheng Zhao, Martin L. Olsson, & Gustaf Edgren. (2021). An agnostic study of associations between ABO and RhD blood group and phenome-wide disease risk. eLife. 10. 24 indexed citations
8.
Sandin, Fredrik, Torsten Dahlén, Anna Lübking, et al.. (2021). Successful tyrosine kinase inhibitor discontinuation outside clinical trials — data from the population‐based Swedish chronic myeloid leukaemia registry. British Journal of Haematology. 193(5). 915–921. 10 indexed citations
9.
Dahlén, Torsten, Germano Ferreira, Peter E. Westerweel, et al.. (2021). Treatment Patterns in Patients with Chronic Myeloid Leukemia in Chronic Phase in the Third Line of TKI Therapy and Beyond Based on Real-World Evidence. Blood. 138(Supplement 1). 1485–1485. 2 indexed citations
10.
Dahlén, Torsten, Gustaf Edgren, Leif Stenke, & Jingcheng Zhao. (2021). Overall Survival and Adverse Events in 378 Ibrutinib-Treated Patients with Chronic Lymphocytic Leukemia - a Swedish Register-Based Nationwide Study. Blood. 138(Supplement 1). 3750–3750. 1 indexed citations
11.
Dahlén, Torsten, et al.. (2021). The frequency of misattributed paternity in Sweden is low and decreasing: A nationwide cohort study. Journal of Internal Medicine. 291(1). 95–100. 12 indexed citations
12.
Zhang, Hanxin, Torsten Dahlén, Atif Ali Khan, Gustaf Edgren, & Andrey Rzhetsky. (2020). Measurable health effects associated with the daylight saving time shift. PLoS Computational Biology. 16(6). e1007927–e1007927. 23 indexed citations
13.
Zhao, Jingcheng, Torsten Dahlén, & Gustaf Edgren. (2020). Costs associated with transfusion therapy in patients with myelodysplastic syndromes in Sweden: a nationwide retrospective cohort study. Vox Sanguinis. 116(5). 581–590. 6 indexed citations
14.
Zhao, Jingcheng, et al.. (2020). Risk of hematological malignancy in blood donors: A nationwide cohort study. Transfusion. 60(11). 2591–2596. 11 indexed citations
15.
Li, Yu, Hanxin Zhang, Ishanu Chattopadhyay, et al.. (2019). Estimating heritability and genetic correlations from large health datasets in the absence of genetic data. Nature Communications. 10(1). 5508–5508. 20 indexed citations
16.
Hirt, Carsten, Sergio Iannazzo, Silvia Chiroli, et al.. (2019). Cost Effectiveness of the Third-Generation Tyrosine Kinase Inhibitor (TKI) Ponatinib, vs. Second-Generation TKIs or Stem Cell Transplant, as Third-Line Treatment for Chronic-Phase Chronic Myeloid Leukemia. Applied Health Economics and Health Policy. 17(4). 555–567. 4 indexed citations
17.
Dahlén, Torsten, Gustaf Edgren, Mats Lambe, et al.. (2016). Cardiovascular Events Associated With Use of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia. Annals of Internal Medicine. 165(3). 161–166. 69 indexed citations
18.
Söderlund, Stina, Torsten Dahlén, Fredrik Sandin, et al.. (2016). Advanced phase chronic myeloid leukaemia (CML) in the tyrosine kinase inhibitor era – a report from the Swedish CML register. European Journal Of Haematology. 98(1). 57–66. 7 indexed citations
19.
20.
Dahlén, Torsten, Gustaf Edgren, Martin Höglund, et al.. (2014). Increased Risk of Cardiovascular Events Associated with TKI Treatment in Chronic Phase Chronic Myeloid Leukemia. Data from Swedish Population-Based Registries. Blood. 124(21). 3134–3134. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mutlu Karkucak Breakdown of academic impact, for papers by Valentina Pierini Breakdown of academic impact, for papers by Radu Vasilescu Breakdown of academic impact, for papers by Sarah N. Gibbs Breakdown of academic impact, for papers by Frode Krøll Breakdown of academic impact, for papers by R. E. Davis Breakdown of academic impact, for papers by Laura Pina Vegas Breakdown of academic impact, for papers by Jessica Samuelsson Breakdown of academic impact, for papers by Corrado Masciullo Breakdown of academic impact, for papers by Peter Haas
Rankless by CCL
2026